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Background/aim: Congenital hypothyroidism (CH) is the most common cause of preventable but irreversible mental retardation in
children, although the risk has been widely abolished by national neonatal screening programs. The aim of this study was to determine,
(a) the cause of CH, (b) the etiological cause of persistent CH and (c) to investigate the role of laboratory and clinical data in predicting
persistent and transient CH.
Materials and methods: Patients diagnosed with CH, who started L-thyroxine treatment and were followed up for at least three years
were included. Patient data were reviewed retrospectively. Serum thyroid hormones were measured four weeks after discontinuation
of therapy at age three or earlier. Cases with a thyroid-stimulating hormone (TSH) value of >10 mIU/mL were accepted as permanent
hypothyroidism, while cases with normal TSH values for six months after cessation were accepted as transient hypothyroidism.
Results: There were 232 treated cases, of whom 108 (46.6%) were female, and 169 (72.8%) were eventually diagnosed with transient
CH. The best cut-off point for predicting permanent status was determined as LT4 cut-off dose ≥1.45 mcg/kg/day. The median (range)
duration of L-thyroxine treatment in transient hypothyroid cases was 24 (range: 6–36) months, and treatment was discontinued before
the age of three years in 64%.
Conclusion: It has been shown that the most common etiologic cause of CH is transient hypothyroidism. The thyroxine dose at the time
of discontinuation of treatment and free thyroxine and TSH levels at the time of diagnosis are essential determinants in distinguishing
permanent/transient CH.
Key words: Congenital hypothyroidism, transient hypothyroidism, permanent hypothyroidism, etiology

1. Introduction
Congenital hypothyroidism (CH) is defined as insufficient
thyroid hormone production as a result of dysfunction of
the hypothalamic-pituitary-thyroid (HPT) axis present
at birth [1]. Thyroid hormone affects almost every organ
system, playing a crucial role in normal growth and
neurological development. CH affects approximately
1:2000 newborns, and, if not detected and treated early and
effectively, can have devastating effects on neurocognitive
development [2]. There has been a widespread introduction
of national neonatal screening programs for the early
detection and rapid diagnosis of CH, as appropriate
replacement treatment with sodium levothyroxine (LT4)
is effective in abolishing most of the deleterious effects of
lack of endogenous thyroid hormone [3].
With screening programs in developed countries, babies
with CH are diagnosed and treated without delay. However,

CH continues to be a significant cause of mental retardation
in countries that do not have a screening program [4].
Depending on the underlying cause, patient suspected of
having CH may be transient or permanent. While permanent
cases due to thyroid gland dysgenesis or defects in thyroidal
enzyme systems that cause dyshormonogenesis, constituted
more than 75%–80% of all patients before the introduction
of screening programs or in the earliest periods of screening,
the frequency of cases with transient CH has gradually
increased. The widespread use of screening programs and
a tendency to reduce cut-off levels of capillary thyroidstimulating hormone (TSH) that will trigger referral for
formal thyroid assessment, has meant that neonates with
lower blood-spot TSH levels are increasingly being referred
[5]. While the frequency of CH in regions with screening
was one in 2000–3000 live births, it was reported that this
rate was one in 6700 live births before screening [6].
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Determining the etiology of raised neonatal TSH is
important in terms of the duration of the treatment [7].
Permanent CH is often caused by thyroid dysgenesis or
dyshormonogenesis, and in these patients, lifelong thyroid
hormone therapy should be continued [1,5]. The etiology
of transient elevated TSH is multifactorial. Although
there are situations in which treatment can be terminated
earlier in transient CH, it is recommended that these
patients be treated up to three years of age to protect the
majority of neurodevelopment which occurs in this period
and is thyroid-hormone dependent and then assessed
subsequently [1,5,8,9].
While the number of referrals from screening
programs increased markedly as TSH threshold values
decreased, the incidence of permanent CH did not
change much [8,10]. For this reason, developing criteria
for the distinction between transient elevated neonatal
TSH and permanent CH is essential. The aims of this
study were: (1) to determine the frequency of transient
and permanent hypothyroidism in cases diagnosed with
CH in our clinic; (2) to determine the etiology in cases
with permanent and transient CH; (3) and to reduce
unnecessary treatment in transient CH by determining
possible parameters that will help to distinguish between
permanent and transient CH.
2.Materials and methods
Medical records of patients diagnosed sequentially with
CH in the pediatric endocrinology clinic between January
2011 and July 2020 were retrospectively reviewed. Cases
diagnosed with CH in the newborn and infancy periods,
started on LT4 treatment, and reached at least three years
old were included. At the same time, patients who started
treatment in other centers, whose thyroid function tests
were known at the time of diagnosis and during followup, and who were followed up regularly in our clinic
were also included in the study. Exclusion criteria were:
(1) patients diagnosed at another center and undergoing
LT4 replacement but lacking data on initial LT4 dose and/
or pretreatment thyroid function tests; (2) patients not
followed up regularly; and (3) follow-up of patients for less
than 3 years.
The age in days, sex, age at diagnosis, age at start of
treatment, consanguinity between parents, gestational
week at delivery, birth weight, family history of
hypothyroidism, iodine exposure, maternal history of
antithyroid drug use, free thyroxine (fT4) at diagnosis, free
triiodothyronine (fT3), serum TSH levels (at diagnosis),
and diagnostic thyroid ultrasonography (USG) results of
the cases were recorded retrospectively from their files.
Additionally, height SDS (standard deviation score),
weight SDS, body mass index (BMI), BMI SDS, and head
circumference SDS data were recorded during diagnosis
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and follow-up. The data of the initial and follow-up LT4
doses of the cases were recorded. The diagnosis of CH was
made following the Consensus of the European Society of
Pediatric Endocrinology, and LT4 treatment was started for
the diagnosed patients [11]. In patients with low-normal
serum fT4 and high serum TSH at the time of diagnosis,
treatment was started at 2.5–15 mcg/kg/day, and the LT4
dose was adjusted according to serum fT4 and TSH levels.
Patients with TSH level <5.6 mIU/mL in the followup and thyroid gland in USG were discontinued at age
three years or earlier. Cases with agenesis or ectopia
detected on USG were accepted as permanent CH,
and LT4 treatments were not discontinued. Serum
thyroid hormones were measured 4–6 weeks after LT4
discontinuation in patients who were three years old or
whose treatment was discontinued before, and patients
with a TSH value >10 mIU/mL after being off-treatment
were evaluated as permanent hypothyroidism and LT4
therapy was reinitiated in these patients. Patients whose
fT4 and TSH values remained within normal limits for six
months after LT4 withdrawal were considered transient
hypothyroidism. Free T4 and TSH were measured again
at the end of the second week in cases with normal fT4
and serum TSH <20 mIU/mL in the neonatal period.
Cases whose TSH value decreased below 10 mIU/mL and
LT4 treatment was not started were accepted as transient
neonatal hyperthyrotropinemia.
BMI was calculated using Bodyweight (kg)/Height²
(m²). The evaluation of height, weight, head circumference,
and BMI SDS was made according to the data prepared by
Neyzi et al. for Turkish children [12]. Obesity was defined
as a BMI of more than +2 SDS for age and sex in all subjects
[12]. In all cases, short stature was defined as a height of
<-2 SDS according to their age and sex [12]. The fT4 (ng/
dL), fT3 (pg/mL), and TSH (mIU/L) levels were measured
using the radioimmunoassay method. Agenesis, ectopia or
hypoplasia reported by USG was accepted as dysgenesis,
and volume increase was accepted as dyshormonogenesis
after evaluating together with the clinical and laboratory
findings.
TSH, fT3, and fT4 levels were measured by 2-chamber
2-step enzymatic immunoassay methods using a Beckman
Coulter DxI 800 device (Beckman Coulter Inc., CA, USA).
Our laboratory uses the reference values provided in the
Beckmann Coulter TSH and fT4 kits, which are TSH
lower and upper limits 0.35–5.6 mIU/mL, and fT4 lower
and upper limits were 0.61–1.32 ng/dL. The fT3 normal
range was 1.9–4.2 pg/mL.
2.1. Statistical methods
Statistical evaluation was done using SPSS (Statistical
Package for Social Science), version 17 (IBM Inc.,
Armonk, NY, USA). Whether the quantitative variables
were normally distributed or not was tested with the one-
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sample Kolmogorov Smirnov test. The Mann-Whitney
U test was used to compare data that were skewed, and
the chi-square test was used to compare categorical data
between groups. Descriptive statistics for the data are given
as median (minimum-maximum) for skewed parameters
and mean±SDS for normally-distributed parameters.
A receiver operator characteristics (ROC) analysis was
applied to determine the cut-off of the LT4 dose at the
time of treatment discontinuation as a predictive criterion
for distinguishing permanent and transient CH, and
the sensitivity and specificity values were calculated for
this threshold value. A p-value of <0.05 was considered
significant.
3. Results
A total of 304 patients’ medical records were scanned.
However, 41 patients were excluded due to insufficient
data, leaving 263. Thirty-one of these followed-up patients
were excluded due to transient hyperthyrotropinemia. The
remaining 232 patients started on L-thyroxine (LT4) were
analyzed. Flow diagram of the follow-up study is shown
in Figure 1.
Of the cases, 108 (46.6%) were female, and 124 were
male. The mean fT3 level at the time of diagnosis was 3.3
± 1.5 ng/dL, the fT4 level was 0.78 ± 0.4 ng/dL, and the
mean serum TSH level was 54.6 ± 34.6 mIU/mL. There
was no difference between the groups with permanent

and transient CH in terms of sex, gestational week,
birth weight, age at diagnosis (days), and age at onset of
treatment (days). However, significant serum fT3, fT4, and
TSH differences were found in patients with permanent
and transient CH. Main characteristics of babies with
permanent and transient CH are shown in Table 1. In
the whole cohort the mean age at diagnosis was median
14 days with a range of 4–90 years, while the mean age at
diagnosis was 17.3 ± 0.9 days in term babies (37 completed
gestational weeks or more), and this rate was 21.4 ± 4.3
days in preterms. While thyroid USG was normal in all
patients in the transient elevated neonatal TSH group,
agenesis in 18 patients (28.6%), ectopic thyroid in four
patients (6.3%), hypoplasia in three patients (4.8%),
and a hemiagenesis in one patient (1.6%) were found
in the permanent hypothyroidism group (Table 1).
Dyshormonogenesis was the most common etiology in
both transient and permanent CH. Distribution of patients
with permanent and transient congenital hypothyroidism
according to their etiology are shown in Table 2 and Table
3.
Mean LT4 doses at baseline, 6th, 12th, 18th, 24th, 30th,
and 36th months were lower in patients with transient CH
than in permanent CH. Follow-up and treatment data of
permanent and transient congenital hypothyroidism cases
are shown in Table 4. When the use of iodized solution
in umbilical care of the baby in the neonatal period was

Figure 1. Flow diagram of the follow-up study.
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Table 1. Main characteristics of babies with permanent and transient CH.

Characteristics

Transient CH
(n: 169)

Permanent CH
(n: 63)

Sex ratio (Female/male)

1:1

0.8:1

Birth weight, g

3.099 ± 600

3.165 ± 468

0.811

Mode of delivery (normal birth: C/S ratio)

0.45:1

0.62:1

0.170

Consanguineous marriage, n (%)

13 (22.4)

19 (12.7)

0.065

CH history, n (%)

13 (22.0)

11 (7.6)

0.050

Birth weight <2500 g, n (%)

7 (11.5)

12 (7.5)

0.245

Gestational age <37 weeks, n (%)

6 (9.8)

15 (9.4)

0.548

Admission age, days

18.0 ± 14.1

18.3 ± 15.5

0.928

Treatment initiation age, days

18.5 ± 14.3

18.4 ± 15.5

0.901

TSH (μU/mL)

74.9 ± 36.7

47.3 ± 30.8

<0.001

fT4 (ng/dL)

0.53 ± 0.39

0.88 ± 0.33

<0.001

fT3 (ng/dL)

2.0 ± 1.6

3.9 ± 1.1

<0.001

Thyroid imaging (USG), n

63

169

Normal

37 (58.7)

162 (95.8%)

Abnormal

26 (41.3%)

7 (4.2%)

Agenesis

18 (28.6%)

-

Ectopic gland

4 (6.3%)

-

Hypoplastic gland

3 (4.8%)

7 (4.2%)

Hemiagenesis

1 (1.6%)

p

<0.001

CH: Congenital hypothyroidism, TSH: Thyroid-stimulating hormone, fT4: Free thyroxine, fT3: Free triiodothyronine,
C/S: Cesarean section, USG: Ultrasonography.
Table 2. Distribution of patients with permanent congenital hypothyroidism according to their etiology.
Male (n = 31)

Female (n = 32)

Total (n = 63)

Thyroid agenesis

6 (19.4%)

12 (37.5%)

18 (28.6%)

Ectopic thyroid

2 (6.5%)

2 (6.3%)

4 (6.3%)

Thyroid hypoplasia

2 (6.5%)

1 (3.1%)

3 (4.8%)

Central hypothyroidism

2 (6.5%)

1 (3.1%)

3 (4.8%)

Prematurity

3 (9.7%)

1 (3.1%)

4 (6.3%)

Dyshormonogenesis

16 (51.6%)

15 (46.9%)

31 (49.2%)

Total

31 (100%)

32 (100%)

63 (100%)

examined, the use of iodinated solution was found in
nine cases. Transient CH was found in six of these cases
and transient hyperthyrotropinemia of the newborn was
found in the remaining three. Treatment was discontinued
at six months in seven (4.1%), at 12 months in 29 cases
(17.2%), at 18 months in 15 cases (8.9%), at 24 months
in 51 cases (30.2%), at 30 months in six cases (3.6%),
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and at 36 months in 61 cases (36.1%). LT4 treatment was
discontinued before 36 months in 108 (63.9%) of the cases
with transient CH.
At the time of diagnosis, mean height SDS was
significantly greater in patients with permanent CH
than in transient CH. However, there was no significant
difference at the end of three years. At the time of diagnosis,
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Table 3. Distribution of patients with transient congenital hypothyroidism according to their etiology.
Male (n = 93)

Female (n = 76)

Total (n = 169)

Iodine exposure

4 (4.3%)

2 (2.6%)

6 (3.6%)

Antithyroid drug use in the mother

2 (2.2%)

1 (1.3%)

3 (1.8%)

Prematurity

10 (10.8%)

6 (7.9%)

16 (9.5%)

Dyshormonogenesis

77 (82.8%)

67 (88.2%)

144 (85.2%)

Total

93 (100%)

76 (100%)

169 (%)

the head circumference SDS was higher in patients with
permanent CH, but this difference disappeared at the end
of one year. Height SDS, weight SDS, BMI SDS, and head
circumference SDS in cases referred because of suspected
congenital hypothyroidism are shown in Table 5. Only one
patient had short stature at the time of diagnosis, and this
patient with transient CH had normal height at the age of
three years. At the end of 3 years of age, short stature was
detected in three cases. Of these cases, two had a history of
small for gestational age (SGA) and were diagnosed with
permanent CH, and one was diagnosed with transient CH
and idiopathic short stature.
As the best criterion for distinguishing between
permanent and transient hypothyroidism, the threshold
of the LT4 dose at the time of discontinuation was ≥1.45
mcg/kg/day by ROC analysis, the area under the curve
(AUC) was 0.992 (95% confidence interval (CI) = 0.985–
1.000), which was statistically significant (p < 0.001). The
diagnostic sensitivity was 100% for this cut-off value, and
the specificity was 90.4% as shown in Figure 2.
4. Discussion
Treatment of CH is easy, inexpensive, and highly effective
[13]. Thyroid hormone is a crucial hormone for brain
development and functions in the fetal and postnatal
periods [14]. Therefore, diagnosis and initiation of
treatment in the first two weeks after birth are critical
for preventing irreversible mental retardation and motor
dysfunction [14,15]. Distinguishing permanent and
transient conditions in patients with suspected CH will
prevent unnecessary treatment in transient patients and
prevent inadequate treatment in permanent patients.
As a result of the screening program conducted in
Turkey between 2008–2010, the frequency of CH was
1/650, and the female/male ratio was similar [9]. In our
study, no difference was found between males and females.
However, consistent with the literature, males were more
common in the group diagnosed with transient CH
[10,16,17]. With the introduction of neonatal screening
programs, the age at diagnosis has decreased significantly.
In studies, the mean age at diagnosis was reported as 11–12

days, and in Turkey, it was 15.7 days in 2010 [9,18,19]. The
main reason why the age at diagnosis was approximately 3
days later than Turkey’s national data might be related to
the delayed TSH elevation of the premature babies included
in the study [11]. In our study, the mean age at diagnosis
was 17.3 days in term babies, while this rate was 21.4 days
in preterms. In addition, the socio-economic status of the
people living in the region, the large population from rural
areas, poor transportation, the distance from the health
service, and the problem in accessing the screening results
affect this delay.
In our clinic, 72.8% of the cases were diagnosed with
transient CH and some cases taking LT4 improved before
the age of three years. Notably, approximately 65% of
transient CH cases discontinued LT4 replacement therapy
before the age of three years at a median duration of 24
months. Kara et al. reported that in 70% of transient CH
cases, the treatment was discontinued before the age of
three and with a median age of 19 months [10]. Although
permanent CH was previously reported more frequently in
the etiology of CH, an increase in the frequency of transient
CH has attracted attention with the widespread use of
screening programs in recent years. In various studies,
transient CH has been reported to make up between 36.5%
and 79.4% of referrals [10,17,20,21]. In the study of Park et
al., the frequency of transient CH was 65% [22]. In various
studies conducted in Turkey, the frequency of transient
CH has been reported between 30%–75% [10,17,23–25].
In our study, the frequency of transient CH was 72.8%,
which is at the high end of the reported ranges.
Among the reasons why the frequency of transient
CH differed between studies, factors such as differences
in inclusion criteria (term/preterm), use of different TSH
threshold values to define transient hypothyroidism,
maternal iodine deficiency, iodine overload in the mother/
baby (often iatrogenic), or the transmission of TSHblocking antibodies to the fetus due to autoimmune
thyroiditis in the mother may play important roles
[2,11,15,26,27]. In a study conducted across Turkey and
investigating iodine status, it was shown that iodine
deficiency is still evident in the Eastern Anatolia region of
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Table 4. Follow-up and treatment data of permanent and transient congenital hypothyroidism cases.
Parameter

Permanent CH

Transient CH

p

Follow-up time, months

≥36

≥36

Median age of treatment discontinuation, months

-

24 (6–36)

L-thyroxine dose (μg/kg/day), n

n = 63

n = 169

Starting dose

63

10.0 ± 3.4

169

7.3 ± 2.8

<0.001

Dose at 6 months

51

3.9 ± 1.2

148

2.1 ± 0.8

<0.001

Dose at 12 months

52

3.0 ± 0.8

142

1.5 ± 0.5

<0.001

Dose at 18 months

52

2.8 ± 0.7

113

1.3 ± 0.4

<0.001

Dose at 24 months

53

2.6 ± 0.7

97

1.2 ± 0.4

<0.001

Dose at 30 months

50

2.5 ± 0.6

56

1.1 ± 0.3

<0.001

Dose at 36 months

51

2.4 ± 0.5

52

0.9 ± 0.3

<0.001

At withdrawal time of L-thyroxine

31

1.4 ± 0.5

169

1.1 ± 0.3

<0.001

Minimum and maximum (min-max) values are given in parentheses.
Table 5. Height SDS, weight SDS, BMI SDS, and head circumference SDS in cases referred because of suspected congenital
hypothyroidism.
Total (n = 232)
(min-max)

Permanent CH
(n = 63)

Transient CH
(n = 169 )

Sex

p
0.260

Female, n(%)

108 (46.8)

32 (50.8)

76 (45.0)

Male, n(%)

123 (53.2)

31 (49.2)

93 (55.0)

Height SDS

0.03 (–2.02/2.2)

0.33 ± 0.75

0.01 ± 0.68

0.026

Weight SDS

0.26 (–1.8/2.85)

0.42 ± 0.82

0.21 ± 0.84

0.222

BMI SDS

0.33 (–2.3/3.0)

0.26 ± 1.11

0.30 ± 0.92

0.840

HC SDS

–1 (–1.93/1.98)

0.07 ± 0.68

–0.25 ± 0.74

0.029

Height SDS

–0.30 (–2.1/3.2)

–0.31 ± 0.88

–0.20 ± 0.86

0.498

Weight SDS

0.12 (–2.0/2.5)

0.23 ± 0.81

0.02 ± 0.87

0.209

BMI SDS

0.39 (–3.0/2.8)

0.64 ± 0.76

0.23 ± 0.94

0.024

HC SDS

0.76 (–1.8/2.06)

0.20 ± 0.73

0.09 ± 0.77

0.448

Height SDS

–0.23 (–2.5/2.7)

–0.08 ± 1.23

–0.19 ± 0.87

0.617

Weight SDS

0.09 (–2.15/2.8)

0.06 ± 1.19

0.15 ± 0.90

0.694

BMI SDS

0.2 (–2.6/3.2)

0.17 ± 1.11

0.27 ± 1.01

0.645

Height SDS

–0.11(–2.8/3.02)

–0.13 ± 1.3

–0.17 ± 0.73

0.866

Weight SDS

0.09 (–3.1/3.30)

0.14 ± 1.4

0.05 ± 0.91

0.742

BMI SDS

0.20 (–2.61/3.2)

0.28 ± 1.10

0.20 ± 0.96

0.747

At diagnosis

1 year old

2 years old

3 years old

SDS: Standard deviation score, BMI: Body mass index, HC: Head circumference. Data are given as means. Minimum and
maximum (min/max) values are given in parentheses.
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Figure 2. The best cut-off point was determined using the Youden
index. The best cut-off point for predicting permanent status was an
LT4 cut-off dose of ≥1.45 mcg/kg/day at the time of beginning a trial
off replacement LT4.
ROC: receiver operating characteristics

Turkey, where the study center is located [26]. Therefore, we
believe that iodine deficiency may have an important role
in the etiology of transient hypothyroidism in our cases,
and could well be associated with the enlarged thyroid
glands found in nearly three quarters of the transient
cases. In our study, the frequency of maternal autoimmune
thyroiditis was unknown and the frequency of transient
hypothyroidism due to maternal TSH receptor-blocking
antibody was not assessed as these antibodies were not
measured in the mother and baby. Our study observed that
hypothyroidism was transient in six of nine cases that were
probably due to use of an iodinated solution in umbilical
care. However, in our study, iodine overload could not be
proven because the urine iodine level was not checked in
infants at the time of diagnosis.
The most common (61%–85%) cause of permanent
CH is accepted to be thyroid dysgenesis [10,27], while the
second most common is dyshormonogenesis (10%–39%)
[16,28]. Since enzyme deficiency in dyshormonogenesis
is inherited in an autosomal recessive fashion,
consanguineous marriage between mother and father is
important in the medical history of these patients, as well
as family history of CH, especially in older siblings [28]. In
our study, the frequency of permanent CH was 27.2%, and
in terms of etiology, thyroid dysgenesis was found in 40.0%

of the cases, dyshormonogenesis in 49.2%, prematurity in
6.3%, and central CH in 4.8%. In our study, the history of
consanguineous marriage in 20% of CH cases diagnosed
with dyshormonogenesis suggests that Mendelian
inheritance should be investigated in the etiology.
It is very important to distinguish permanency and
transiency in CH cases, both to prevent unnecessary
treatment for transient cases and to ensure that
permanent hypothyroidism cases receive appropriate
treatment. Various criteria have been investigated to
predict transient and permanent hypothyroidism in cases
where scintigraphy could be performed for etiological
evaluation at the time of diagnosis or in cases with the
ectopic thyroid gland in scintigraphy. Among these
criteria, the most investigated are serum fT4, TSH levels,
and LT4 dose at diagnosis and follow-up. Reports vary
on this subject. Although it has been reported that fT4 at
the time of diagnosis may be effective in determination
in some studies and TSH in others, there are also studies
stating that both are not determinative [8,17,24,25,29,30].
In their study, Tamam et al. reported that TSH levels were
significantly higher and free T4 levels were significantly
lower in the permanent hypothyroidism group at the time
of diagnosis compared to the transient hypothyroidism
group [30]. In our study, fT4 and fT3 levels were
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significantly lower in permanent CH, while TSH was
higher at diagnosis. These results suggested that, contrary
to most studies, fT4, fT3, and TSH levels at the time of
diagnosis can be a criterion for distinguishing permanent
and transient hypothyroidism.
Most studies reported that the LT4 dose of the
permanent group was higher than the transient group at
LT4 withdrawal [10,17,20,24]. In our study, the dose of
LT4 at the time of discontinuation of treatment (which
was determined as a predictive criterion for the differential
diagnosis of permanent and transient hypothyroidism)
was evaluated. The best cut-off point for predicting
permanent status was determined as an LT4 cut-off dose of
≥1.45 mcg/kg/day. When this threshold value was taken,
the probability of predicting the permanent state was 81%
with a specificity of 90%.
If CH is not treated, it causes irreversible mental
retardation and reversible short stature [4]. Neonatal
screening programs for CH have successfully improved
both cognitive and growth outcomes in recent years [4,11].
In our study, while the mean height SDS was significantly
higher in patients with permanent CH at the time of
diagnosis than in transient CH, no difference was found
between them at the end of three years. While the head
circumference SDS at the time of diagnosis was higher in
patients with permanent CH, this difference disappeared
at the end of one year. At the end of three years, short
stature was detected in only three patients (1.2%). While
two of these patients were SGA, one was diagnosed with
idiopathic short stature. This situation shows once again

how important the treatment for physical and mental
development in patients with CH is.
The most important limitation of our study is that it
was designed retrospectively. In addition, maternal and
baby urinary iodine levels were not checked, which will
probably have affected thyroid functions, especially given
that our region is a known area of iodine deficiency.
Furthermore, transplacental transmission of maternal
thyroid autoantibodies and maternal drugs potentially
affecting thyroid functions were not evaluated. Another
limitation is the inclusion of patients diagnosed in other
centers, although thyroid function tests are performed
with a similar method and reference intervals are similar.
In conclusion, the frequency of transient CH was 72.8%.
Furthermore, LT4 dose at the time of discontinuation of
treatment was shown to be predictive of the permanence
of CH versus transient thyroid dysfunction while fT4 and
TSH levels at the time of diagnosis were also significant
among the predictive criteria in the differential diagnosis
of transient and permanent CH.
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